Related Experiment Videos
The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study
M Tunca1, E Tankurt, H Akbaylar Akpinar
1Department of Internal Medicine, Dokuz Eylül University School of Medicine, Balçova, Izmir, Turkey.
Abstract:
About a quarter of familial Mediterranean fever (FMF) patients have recurrent painful attacks of polyserositis despite regular colchicine treatment. There is no known alternative drug for colchicine-resistant cases. We had previously observed a patient with FMF whose painful attacks disappeared during the 6 month period of interferon alpha (IFN) treatment for his chronic hepatitis B. The objective of the present study was to investigate the possible beneficial effect of IFN on these episodes. Twenty-one consecutive attacks in seven adult patients with FMF were treated at early onset with IFN, the dosage being 3-10 million I U s.c. Eighteen of the 21 attacks could be halted in a mean time of 3.05 h, while the intensity of abdominal pain remained very low. Observed side-effects were generally mild and acceptable. IFN may be a useful adjunct for the treatment of colchicine-resistant attacks in FMF patients.
Insights
Interferon alpha (IFN) shows promise for Familial Mediterranean Fever (FMF) patients resistant to colchicine. Early IFN treatment effectively halted painful polyserositis attacks with mild side effects.
Area of Science:
- Immunology
- Rheumatology
- Gastroenterology
Background:
- Familial Mediterranean Fever (FMF) is an autoinflammatory disorder characterized by recurrent polyserositis.
- A significant portion of FMF patients exhibit resistance to standard colchicine treatment.
- No established alternative therapies exist for colchicine-resistant FMF.
Purpose of the Study:
- To evaluate the efficacy of Interferon alpha (IFN) as a treatment for colchicine-resistant Familial Mediterranean Fever (FMF) attacks.
- To assess the safety and tolerability of IFN in FMF patients.
Main Methods:
- Seven adult FMF patients with colchicine-resistant attacks were enrolled.
- Twenty-one FMF attacks were treated with subcutaneous IFN (3-10 million IU) at early onset.
- Attack duration, pain intensity, and side effects were monitored.
Main Results:
- IFN successfully halted 18 out of 21 treated FMF attacks.
- The mean time to halt an attack was 3.05 hours.
- Abdominal pain intensity remained low, and observed side effects were generally mild and acceptable.
Conclusions:
- Interferon alpha (IFN) may serve as a valuable adjunctive therapy for managing colchicine-resistant Familial Mediterranean Fever (FMF) attacks.
- IFN demonstrates a favorable efficacy and safety profile in this patient cohort.
- Further research is warranted to confirm these findings and establish optimal treatment protocols.